CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Rating of "Hold" from Brokerages

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) have earned an average rating of "Hold" from the nineteen ratings firms that are currently covering the company, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $74.94.

A number of equities analysts have commented on CRSP shares. Truist Financial reduced their target price on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a "buy" rating for the company in a report on Monday, August 12th. Stifel Nicolaus cut their target price on CRISPR Therapeutics from $60.00 to $59.00 and set a "hold" rating on the stock in a research report on Tuesday, August 6th. Rodman & Renshaw started coverage on shares of CRISPR Therapeutics in a report on Friday, August 2nd. They issued a "buy" rating and a $90.00 target price for the company. Royal Bank of Canada restated a "sector perform" rating and set a $53.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $84.00 price objective on shares of CRISPR Therapeutics in a research note on Wednesday.

CRISPR Therapeutics Trading Down 0.2 %

Shares of NASDAQ CRSP traded down $0.11 during midday trading on Friday, hitting $51.77. The company's stock had a trading volume of 748,691 shares, compared to its average volume of 1,453,198. The stock has a fifty day moving average price of $47.38 and a 200 day moving average price of $52.24. The firm has a market capitalization of $4.40 billion, a price-to-earnings ratio of -16.06 and a beta of 1.67. CRISPR Therapeutics has a one year low of $43.42 and a one year high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, beating the consensus estimate of ($1.42) by $0.41. The firm had revenue of $0.60 million for the quarter, compared to the consensus estimate of $6.65 million. During the same period in the previous year, the company earned ($1.41) earnings per share. On average, equities research analysts predict that CRISPR Therapeutics will post -5.57 earnings per share for the current fiscal year.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,089 shares of the business's stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $50,398.92. Following the completion of the transaction, the general counsel now owns 62,597 shares in the company, valued at $2,896,989.16. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, General Counsel James R. Kasinger sold 1,089 shares of the firm's stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $50,398.92. Following the completion of the sale, the general counsel now owns 62,597 shares of the company's stock, valued at $2,896,989.16. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Samarth Kulkarni sold 4,293 shares of the company's stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $198,680.04. Following the completion of the transaction, the chief executive officer now owns 226,540 shares of the company's stock, valued at approximately $10,484,271.20. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 4.10% of the stock is owned by corporate insiders.

Institutional Trading of CRISPR Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Global Trust Asset Management LLC increased its stake in CRISPR Therapeutics by 150.0% in the second quarter. Global Trust Asset Management LLC now owns 500 shares of the company's stock valued at $27,000 after purchasing an additional 300 shares during the last quarter. Larson Financial Group LLC increased its position in CRISPR Therapeutics by 95.5% in the 2nd quarter. Larson Financial Group LLC now owns 565 shares of the company's stock valued at $31,000 after acquiring an additional 276 shares during the period. GPS Wealth Strategies Group LLC lifted its holdings in CRISPR Therapeutics by 99.7% in the second quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company's stock worth $33,000 after purchasing an additional 307 shares during the period. Itau Unibanco Holding S.A. bought a new position in shares of CRISPR Therapeutics in the second quarter valued at approximately $35,000. Finally, Denver PWM LLC acquired a new stake in CRISPR Therapeutics in the 2nd quarter valued at about $45,000. 69.20% of the stock is owned by hedge funds and other institutional investors.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.